Abstract |
Chondroitin sulfate (CS) is recommended as a therapeutic intervention in the multimodal approach of osteoarthritis (OA) management. CS has been studied extensively to describe its pharmacology (pharmacokinetic, in vitro and in vivo effects) and its clinical efficacy. Various results have been reported depending on the system of evaluation (model, dosage and duration) and the source of CS (origin and quality). The purpose of this review was to gather most of the available information about CS and to discuss its potency in OA management.
|
Authors | Yves Henrotin, Mariane Mathy, Christelle Sanchez, Cecile Lambert |
Journal | Therapeutic advances in musculoskeletal disease
(Ther Adv Musculoskelet Dis)
Vol. 2
Issue 6
Pg. 335-48
(Dec 2010)
ISSN: 1759-7218 [Electronic] England |
PMID | 22870459
(Publication Type: Journal Article)
|